Connecting via Winsock to STN

Welcome to STN International! Enter x:x

L * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:17:37 ON 19 APR 2010

=>
=> file reg

=> s montelukast
L1 8 MONTELUKAST

=> d 1-8

L1 ANSWER 1 OF 8 REGISTRY COPYRIGHT 2010 ACS on STN
RN 1021952-73-7 REGISTRY
ED Entered STN: 22 May 2008
CN L-Arginine, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetate (1:1) (CA INDEX NAME)
OTHER NAMES:
CN Montelukast arginine salt
FS STEREOSEARCH
MF C35 H36 Cl N O3 S . C6 H14 N4 O2
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 158966-92-8
CMF C35 H36 Cl N O3 S

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 74-79-3
CMF C6 H14 N4 O2

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 2 OF 8 REGISTRY COPYRIGHT 2010 ACS on STN
RN 880769-33-5 REGISTRY
ED Entered STN: 18 Apr 2006
CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, compd. with N-(1-methylethyl)-2-propanamine (1:1) (CA INDEX NAME)
OTHER NAMES:
CN Montelukast diisopropylamine salt
FS STEREOSEARCH
MF C35 H36 Cl N O3 S . C6 H15 N
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 158966-92-8
CMF C35 H36 Cl N O3 S

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 108-18-9
CMF C6 H15 N

i-Pr—NH—Pr-i

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 3 OF 8 REGISTRY COPYRIGHT 2010 ACS on STN
RN 880769-32-4 REGISTRY
ED Entered STN: 18 Apr 2006
CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, compd. with N-(phenylmethyl)benzenemethanamine (1:1) (CA INDEX NAME)
OTHER NAMES:
CN Montelukast dibenzylamine salt
FS STEREOSEARCH
MF C35 H36 Cl N O3 S . C14 H15 N
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 158966-92-8
CMF C35 H36 Cl N O3 S

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 103-49-1
CMF C14 H15 N

Ph—CH2—NH—CH2—Ph

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 4 OF 8 REGISTRY COPYRIGHT 2010 ACS on STN
RN 851755-58-3 REGISTRY
ED Entered STN: 07 Jun 2005
CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, compd. with 2-methyl-2-propanamine (1:1) (CA INDEX NAME)
OTHER NAMES:
CN Montelukast tert-butylamine
FS STEREOSEARCH
MF C35 H36 Cl N O3 S . C4 H11 N
SR CA
LC STN Files: CA, CAPLUS, CASREACT, CHEMLIST, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 158966-92-8
CMF C35 H36 Cl N O3 S

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 75-64-9
CMF C4 H11 N

11 REFERENCES IN FILE CA (1907 TO DATE)
11 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 5 OF 8 REGISTRY COPYRIGHT 2010 ACS on STN
RN 577953-88-9 REGISTRY
ED Entered STN: 03 Sep 2003
CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, compd. with N-cyclohexylcyclohexanamine (1:1) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 2-[1-[[[(1R)-1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropyl]acetic acid dicyclohexylamine salt
CN Montelukast dicyclohexylamine salt
FS STEREOSEARCH
MF C35 H36 Cl N O3 S . C12 H23 N
SR CA
LC STN Files: CA, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 158966-92-8
CMF C35 H36 Cl N O3 S

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 101-83-7
CMF C12 H23 N



18 REFERENCES IN FILE CA (1907 TO DATE)
18 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 6 OF 8 REGISTRY COPYRIGHT 2010 ACS on STN
RN 577953-85-6 REGISTRY
ED Entered STN: 03 Sep 2003
CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, calcium salt (2:1) (CA INDEX NAME)
OTHER NAMES:
CN Montelukast calcium
FS STEREOSEARCH
MF C35 H36 Cl N O3 S . 1/2 Ca
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL
CRN (158966-92-8)

Absolute stereochemistry.
Double bond geometry as shown.



●1/2 Ca

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 7 OF 8 REGISTRY COPYRIGHT 2010 ACS on STN
RN 158966-92-8 REGISTRY
ED Entered STN: 15 Nov 1994
CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cyclopropaneacetic acid, 1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, [R-(E)]-
OTHER NAMES:
CN 1-[[[(R)-1-[3-[(E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid
CN 2-[1-[[[(1R)-1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropyl]acetic acid
CN Montelukast
CN [1-[[[(1R)-1-[3-[(E)-2-(7-Chloroquinolin-2-yl)vinyl]phenyl]-3-[2-(1-

hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropyl]acetic acid
FS STEREOSEARCH
MF C35 H36 Cl N O3 S
CI COM
SR World Health Organization (WHO)
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CIN, DDFU, DRUGU, EMBASE, HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

849 REFERENCES IN FILE CA (1907 TO DATE)
21 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
852 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 8 OF 8 REGISTRY COPYRIGHT 2010 ACS on STN
RN 151767-02-1 REGISTRY
ED Entered STN: 16 Dec 1993
CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, sodium salt (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, monosodium salt (9CI)
CN Cyclopropaneacetic acid, 1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, monosodium salt, [R-(E)]-
OTHER NAMES:
CN 1-[[[(R)-1-[3-[(E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid sodium salt

CN 2-[1-[[[(1R)-1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropyl]acetic acid sodium salt
CN MK 476
CN Momazol
CN Montair
CN Montelukast monosodium salt
CN Montelukast sodium
CN Shantroz
CN Singulair
CN Sodium 2-[1-[[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)vinyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropyl]acetate
CN Sodium montelukast
FS STEREOSEARCH
MF C35 H36 Cl N O3 S . Na
CI COM
SR US Adopted Names Council (USAN)
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, EMBASE, HSDB*, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PATDPASPC, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
CRN (158966-92-8)

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

316 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
320 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> s 158966-92-8/rn
L2            1 158966-92-8/RN

=> d

L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2010 ACS on STN
RN   158966-92-8  REGISTRY
ED   Entered STN:  15 Nov 1994
CN   Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-
     quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-
     methylethyl)phenyl]propyl]thio]methyl]-  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Cyclopropaneacetic acid, 1-[[[1-[3-[2-(7-chloro-2-
     quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-
     methylethyl)phenyl]propyl]thio]methyl]-, [R-(E)]-
OTHER NAMES:
CN   1-[[[(R)-1-[3-[(E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-
     hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid
CN   2-[1-[[[(1R)-1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-
     hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropyl]acetic acid
CN   Montelukast
CN   [1-[[[(1R)-1-[3-[(E)-2-(7-Chloroquinolin-2-yl)vinyl]phenyl]-3-[2-(1-
     hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropyl]acetic
     acid
FS   STEREOSEARCH
MF   C35 H36 Cl N O3 S
CI   COM
SR   World Health Organization (WHO)
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, BIOSIS, BIOTECHNO, CA,
       CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CIN, DDFU, DRUGU, EMBASE, HSDB*,
       IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*,
       PATDPASPC, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN,
       USPAT2, USPATFULL
         (*File contains numerically searchable property data)
     Other Sources:   WHO

Absolute stereochemistry.
Double bond geometry as shown.
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**
```

```
            849 REFERENCES IN FILE CA (1907 TO DATE)
             21 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
            852 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> file ca
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    28.32      28.54

FILE 'CA' ENTERED AT 10:22:29 ON 19 APR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 15 Apr 2010 VOL 152 ISS 17
FILE LAST UPDATED: 15 Apr 2010  (20100415/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Feb 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Feb 2010

CA now includes complete International Patent Classification (IPC)
reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d his

     (FILE 'HOME' ENTERED AT 10:17:37 ON 19 APR 2010)

     FILE 'REGISTRY' ENTERED AT 10:17:46 ON 19 APR 2010
L1             8 S MONTELUKAST
L2             1 S 158966-92-8/RN

     FILE 'CA' ENTERED AT 10:22:29 ON 19 APR 2010

=> s l2
L3           849 L2

=> s l2 and crystalline
           849 L2
         91832 CRYSTALLINE
```

L4 5 L2 AND CRYSTALLINE

=> d ibib abs hitstr 1-5

L4 ANSWER 1 OF 5 CA COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 150:501196 CA
TITLE: Novel crystalline salts of montelukast
INVENTOR(S): O'Shea, Paul
PATENT ASSIGNEE(S): Merck Frosst Canada Ltd., Can.
SOURCE: PCT Int. Appl., 31pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009052625	A1	20090430	WO 2008-CA1875	20081023

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2007-342P P 20071025

AB The present application relates to crystalline 1,2-ethanedisulfonic acid salt and N,N'-dibenzylethylenediamine salt of montelukast. The salts are useful as therapeutic agents for the treatment of leukotriene mediated diseases and disorders. This application also relates to processes and intermediates for preparing the said salts and pharmaceutical compns. comprising the salts and optionally other therapeutic agents.

IT 158966-92-8, Montelukast
RL: RCT (Reactant); RACT (Reactant or reagent)
(novel crystalline salts of montelukast)

RN 158966-92-8 CA

CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 5 CA COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 150:501152 CA
TITLE: Crystalline montelukast cyclopropylamine salt for preparation of pure amorphous sodium salt
INVENTOR(S): Huguet Clotet, Juan; Peirats Masia, Jordi
PATENT ASSIGNEE(S): Inke, S.A., Spain
SOURCE: PCT Int. Appl., 29pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009053424	A1	20090430	WO 2008-EP64345	20081023
WO 2009053424	A9	20090806		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 2053043	A1	20090429	EP 2007-380294	20071026

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS

PRIORITY APPLN. INFO.: EP 2007-380294 A 20071026
OTHER SOURCE(S): CASREACT 150:501152; MARPAT 150:501152
GI



I

AB The present invention refers to the novel cyclopropylamine salt of montelukast (I) in crystalline form and its use in the process for the preparation of highly pure amorphous montelukast sodium. I is prepared from [1-[1-(R)-(3-bromophenyl)-3-[2-(1-hydroxy-1-methylethyl)phenyl]propylsulfanylmethyl]cyclopropyl]acetic acid and 7-chloro-2-vinylquinoline. I is treated with cyclopropylamine to give a polymorphic form and this is converted to the sodium salt.

IT 158966-92-8P, Montelukast
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(crystalline montelukast cyclopropylamine salt for preparation of pure amorphous sodium salt)

RN 158966-92-8 CA

CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 5 CA COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 150:456452 CA
TITLE: Crystalline montelukast cyclopropylamine salt for preparation of pure amorphous sodium salt
INVENTOR(S): Huguet Clotet, Joan; Peirats Masia, Jordi
PATENT ASSIGNEE(S): Inke, S.A., Spain
SOURCE: Eur. Pat. Appl., 17pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 2053043	A1	20090429	EP 2007-380294	20071026
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
US 20090111849	A1	20090430	US 2007-965730	20071227
WO 2009053424	A1	20090430	WO 2008-EP64345	20081023
WO 2009053424	A9	20090806		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				

PRIORITY APPLN. INFO.: EP 2007-380294 A 20071026
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB The present invention refers to the novel cyclopropylamine salt of montelukast (I) in crystalline form and its use in the process for the preparation of highly pure amorphous montelukast sodium. I is prepared from [1-[1-(R)-(3-bromophenyl)-3-[2-(1-hydroxy-1-methylethyl)phenyl]propylsulfanylmethyl]cyclopropyl]acetic acid and 7-chloro-2-vinylquinoline. I is treated with cyclopropylamine to give a polymorphic form and this is converted to the sodium salt.
IT 158966-92-8P, Montelukast
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(crystalline montelukast cyclopropylamine salt for preparation of pure amorphous sodium salt)
RN 158966-92-8 CA
CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 CA COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 149:582517 CA
TITLE: Solid dosage forms of pharmaceutical carriers
INVENTOR(S): Cengic, Dzenana; Darmuzey, Olivia; Macleod, Graeme
PATENT ASSIGNEE(S): FMC Corporation, USA
SOURCE: PCT Int. Appl., 43pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008140460	A1	20081120	WO 2007-US11762	20070516

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: WO 2007-US11762 20070516

AB A solid form comprising at least one film enrobing a compacted fill material having at least one active material contained in a matrix and having low friability, a d. of at least 0.5 g/mL based on the total solid volume of the solid form and a tensile strength less than 0.9 MPa and which exhibits a controlled release profile for release of the active material. Zero order release may be achieved.

IT 158966-92-8, Montelukast
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solid dosage forms of pharmaceutical carriers)

RN 158966-92-8 CA

CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-

quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 5 CA COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 149:556455 CA
TITLE: Process for the preparation of amorphous Montelukast sodium salt wherein crystalline forms of methanesulfonate intermediate and Montelukast are not isolated.
INVENTOR(S): Zyla, Daniel; Rynkiewicz, Robert; Krzyzanowski, Mariusz; Ramza, Jan
PATENT ASSIGNEE(S): Zaklady Farmaceutyczne Polpharma S. A., Pol.
SOURCE: PCT Int. Appl., 22pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008136693	A2	20081113	WO 2008-PL33	20080430
WO 2008136693	A3	20081231		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,

AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
EP 2142508 A2 20100113 EP 2008-741772 20080430
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR
US 20100069641 A1 20100318 US 2009-597746 20091026
IN 2009KN04035 A 20100319 IN 2009-KN4035 20091120
CN 101679268 A 20100324 CN 2008-80017789 20091127
PRIORITY APPLN. INFO.: PL 2007-382346 A 20070502
WO 2008-PL33 W 20080430

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 149:556455

AB Amorphous Montelukast sodium was prepared by (1) reaction of 2-[2-(3S)-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-(hydroxypropyl)phenyl]-2-propanol with MeSO2Cl in the presence of a tertiary amine, (2) filtration of precipitated tertiary amine salt and reaction of the crude methanesulfonate ester with [1-(mercaptomethyl)cyclopropyl]acetic acid disodium salt, (3) isolation of crystalline 1-[[[(1R)-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid tert-butylamine salt, (4) purification of this salt until the product has high pharmaceutical purity, and (5) conversion of the purified salt to the title compound

IT 158966-92-8P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for the preparation of amorphous Montelukast sodium salt wherein crystalline forms of methanesulfonate intermediate and Montelukast are not isolated)

RN 158966-92-8 CA

CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



=> s montelukast acetic acid
1166 MONTELUKAST
295818 ACETIC

```
       4930804 ACID
L5           0 MONTELUKAST ACETIC ACID
                 (MONTELUKAST(W)ACETIC(W)ACID)

=> file reg
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                44.11      72.65

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                -4.00      -4.00

FILE 'REGISTRY' ENTERED AT 10:31:48 ON 19 APR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   18 APR 2010  HIGHEST RN 1219538-51-8
DICTIONARY FILE UPDATES:  18 APR 2010  HIGHEST RN 1219538-51-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s montelukast acetic acid
             8 MONTELUKAST
       1440459 ACETIC
      13010774 ACID
L6           0 MONTELUKAST ACETIC ACID
                 (MONTELUKAST(W)ACETIC(W)ACID)

=> s
1_(((1(R)-(3-(2-(7-chloro-2-quinolinyl)theynyl)-phenyl)-3-(2-(1-hydroxy-1-methylethy
l)phenyl)propyl)thio)methyl) cyclopropane acetic acid
MISSING OPERATOR '1_(('

=> s
1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)theynyl)-phenyl)-3-(2-(1-hydroxy-1-methylethy
l)phenyl)propyl)thio)methyl) cyclopropane acetic acid
MISSING OPERATOR '1-(('

=> s
"1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)theynyl)-phenyl)-3-(2-(1-hydroxy-1-methyleth
yl)phenyl)propyl)thio)methyl) cyclopropane acetic acid"
```

```
      35618330 "1"
      35618330 "1"
       1044942 "R"
      32523011 "3"
      39413734 "2"
       6974462 "7"
      10147850 "CHLORO"
      39413734 "2"
        457582 "QUINOLINYL"
             0 "THEYNYL"
      26184926 "PHENYL"
      32523011 "3"
      39413734 "2"
      35618330 "1"
       5773717 "HYDROXY"
      35618330 "1"
       3696380 "METHYLETHYL"
      26184926 "PHENYL"
       5474449 "PROPYL"
       5917305 "THIO"
      32460110 "METHYL"
        202402 "CYCLOPROPANE"
       1440459 "ACETIC"
      13010774 "ACID"
L7           0 "1-(((1(R)-(3-(2-(7-CHLORO-2-QUINOLINYL)THEYNYL)-PHENYL)-3-(2-(1
                -HYDROXY-1-METHYLETHYL)PHENYL)PROPYL)THIO)METHYL) CYCLOPROPANE
                ACETIC ACID"
                  ("1"(W)"1"(W)"R"(W)"3"(W)"2"(W)"7"(W)"CHLORO"(W)"2"(W)"QUINOLI
                  NYL"(W)"THEYNYL"(W)"PHENYL"(W)"3"(W)"2"(W)"1"(W)"HYDROXY"(W)"1
                  "(W)"METHYLETHYL"(W)"PHENYL"(W)"PROPYL"(W)"THIO"(W)"METHYL"(W)
                  "CYCLOPROPANE"(W)"ACETIC"(W)"ACID")

=> file ca
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                149.97     222.62

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                  0.00      -4.00

FILE 'CA' ENTERED AT 10:33:42 ON 19 APR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 15 Apr 2010 VOL 152 ISS 17
FILE LAST UPDATED: 15 Apr 2010 (20100415/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2010

CA now includes complete International Patent Classification (IPC)
reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s
"1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)theynyl)-phenyl)-3-(2-(1-hydroxy-1-methyleth
yl)phenyl)propyl)thio)methyl) cyclopropane acetic acid"
10007293 "1"
10007293 "1"
1339065 "R"
7528165 "3"
9946058 "2"
3006540 "7"
378721 "CHLORO"
9946058 "2"
2863 "QUINOLINYL"
0 "THEYNYL"
380998 "PHENYL"
7528165 "3"
9946058 "2"
10007293 "1"
495981 "HYDROXY"
10007293 "1"
13243 "METHYLETHYL"
380998 "PHENYL"
106208 "PROPYL"
72813 "THIO"
1128811 "METHYL"
18987 "CYCLOPROPANE"
295818 "ACETIC"
4930804 "ACID"
L8 0 "1-(((1(R)-(3-(2-(7-CHLORO-2-QUINOLINYL)THEYNYL)-PHENYL)-3-(2-(1
-HYDROXY-1-METHYLETHYL)PHENYL)PROPYL)THIO)METHYL) CYCLOPROPANE
ACETIC ACID"
("1"(W)"1"(W)"R"(W)"3"(W)"2"(W)"7"(W)"CHLORO"(W)"2"(W)"QUINOLI
NYL"(W)"THEYNYL"(W)"PHENYL"(W)"3"(W)"2"(W)"1"(W)"HYDROXY"(W)"1
"(W)"METHYLETHYL"(W)"PHENYL"(W)"PROPYL"(W)"THIO"(W)"METHYL"(W)
"CYCLOPROPANE"(W)"ACETIC"(W)"ACID")

=> shr05/00005
SHR05 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s hr05/00005

```
'00005' IS NOT A VALID FIELD CODE
L9            0 HR05/00005

=> s 20070225325
L10           0 20070225325

=> file uspatfull
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                   55.48     278.10

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    0.00      -4.00

FILE 'USPATFULL' ENTERED AT 10:34:52 ON 19 APR 2010
CA INDEXING COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 15 Apr 2010 (20100415/PD)
FILE LAST UPDATED: 15 Apr 2010 (20100415/ED)
HIGHEST GRANTED PATENT NUMBER: US7698747
HIGHEST APPLICATION PUBLICATION NUMBER: US20100095420
CA INDEXING IS CURRENT THROUGH 15 Apr 2010 (20100415/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 15 Apr 2010 (20100415/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2010

USPATFULL now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

To ensure comprehensive retrieval of US patent information, including
US patent application information, search USPATFULL in combination with
USPAT2.

=> s 20070225325
L11           0 20070225325

=> s solid forms of montelukast ackd
       1495856 SOLID
       2264471 FORMS
          2310 MONTELUKAST
            73 ACKD
L12           0 SOLID FORMS OF MONTELUKAST ACKD
                (SOLID(W)FORMS(1W)MONTELUKAST(W)ACKD)

=> s solid forms of montelukast acid
       1495856 SOLID
       2264471 FORMS
          2310 MONTELUKAST
       1087999 ACID
L13           1 SOLID FORMS OF MONTELUKAST ACID
                (SOLID(W)FORMS(1W)MONTELUKAST(W)ACID)

=> d

L13  ANSWER 1 OF 1  USPATFULL on STN
AN     2007:257380  USPATFULL
```

```
TI     Solid Forms of Montelukast Acid
IN     Mestrovic, Ernest, Bjelovar, CROATIA
       Horvat, Michaela, Sesvete, CROATIA
       Devcic, Maja, Pozega, CROATIA
       Avdagic, Amir, Zagreb, CROATIA
       Cincic, Dominik, Zagreb, CROATIA
       Marinkovic, Marina, Sesvete, CROATIA
PA     PLIVA-ISTRAZIVANJE I RAZVOJ D.O.O., Zagreb, CROATIA (non-U.S.
       corporation)
PI     US 20070225325      A1  20070927
AI     US 2005-587537      A1  20050119 (10)
       WO 2005-HR5             20050119
                               20070607  PCT 371 date
PRAI   US 2004-540307P         20040128 (60)
DT     Utility
FS     APPLICATION
LN.CNT 666
INCL   INCLM: 514/311.000
       INCLS: 546/180.000
NCL    NCLM:  514/311.000
       NCLS:  546/180.000
IC     IPCI   C07D0215-00 [I,A]
       IPCR   C07D0215-00 [I,C]; C07D0215-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> file ca
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     2.69     280.79

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -4.00

FILE 'CA' ENTERED AT 10:35:22 ON 19 APR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 15 Apr 2010 VOL 152 ISS 17
FILE LAST UPDATED: 15 Apr 2010  (20100415/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Feb 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Feb 2010

CA now includes complete International Patent Classification (IPC)
```

reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> s l13
       1193270 SOLID
        628813 FORMS
          1166 MONTELUKAST
       4930804 ACID
L14           0 SOLID FORMS OF MONTELUKAST ACID
                (SOLID(W)FORMS(1W)MONTELUKAST(W)ACID)

=> s us 20070225325
        124805 US
             0 20070225325
L15           0 US 20070225325
                (US(W)20070225325)

=> s mestrovic/au
L16           0 MESTROVIC/AU

=> s mestrovic?/au
L17          95 MESTROVIC?/AU

=> s l17 and horvat?/au
         11056 HORVAT?/AU
L18           5 L17 AND HORVAT?/AU

=> d ibib 1-5

L18  ANSWER 1 OF 5  CA  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:         151:187935  CA
TITLE:                    Structural, Spectroscopic and Thermal Characterisation
                          of bis (dibenzoylmethanato)Cd(II) Adducts with
                          Dimethylsulfoxide and Water
AUTHOR(S):                Halasz, Ivan; Horvat, Michaela; Biljan,
                          Tomislav; Mestrovic, Ernest
CORPORATE SOURCE:         Chemistry Department, Faculty of Science, University
                          of Zagreb, Zagreb, 10000, Croatia
SOURCE:                   Journal of Chemical Crystallography (2008), 38(10),
                          793-800
                          CODEN: JCCYEV; ISSN: 1074-1542
PUBLISHER:                Springer
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
OTHER SOURCE(S):          CASREACT 151:187935
OS.CITING REF COUNT:      1     THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
                                (1 CITINGS)
REFERENCE COUNT:          22    THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18  ANSWER 2 OF 5  CA  COPYRIGHT 2010 ACS on STN
```

ACCESSION NUMBER: 144:474927 CA
TITLE: Crystal form of celecoxib
INVENTOR(S): Mestrovic, Ernest; Horvat, Michaela ; Kwokal, Ana; Devcic, Maja; Filic, Darko; Danilovski, Aleksandar; Cetina-Cizmek, Biserka; Mundorfer, Tina
PATENT ASSIGNEE(S): Pliva - Istrazivanje I Razvoj d.o.o., Croatia
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006051340	A1	20060518	WO 2005-HR41	20050721
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2574326	A1	20060518	CA 2005-2574326	20050721
EP 1768961	A1	20070404	EP 2005-826859	20050721
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				

PRIORITY APPLN. INFO.: US 2004-590827P P 20040722
WO 2005-HR41 W 20050721
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 5 CA COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 143:292196 CA
TITLE: An investigation into the thermal behavior of a model drug mixture with amorphous trehalose
AUTHOR(S): Horvat, M.; Mestrovic, E.; Danilovski, A.; Craig, D. Q. M.
CORPORATE SOURCE: PLIVA-Research and Development Ltd., Zagreb, HR-10000, Croatia
SOURCE: International Journal of Pharmaceutics (2005), 294(1-2), 1-10
CODEN: IJPHDE; ISSN: 0378-5173
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 4 OF 5 CA COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 143:199868 CA
TITLE: Solid forms of montelukast
INVENTOR(S): Mestrovic, Ernest; Horvat, Michaela ; Devcic, Maja; Avdagic, Amir; Ciccic, Dominik; Marinkovic, Marina
PATENT ASSIGNEE(S): Pliva- Istrazivanje I Razvoj D.O.O., Croatia
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005073194	A2	20050811	WO 2005-HR5	20050119
WO 2005073194	A3	20060504		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1709001	A2	20061011	EP 2005-702162	20050119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
US 20070225325	A1	20070927	US 2007-587537	20070607
PRIORITY APPLN. INFO.:			US 2004-540307P P	20040128
			WO 2005-HR5 W	20050119

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 5 OF 5 CA COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 136:374675 CA
TITLE: Thermal behavior of diclofenac sodium: decomposition and melting characteristics
AUTHOR(S): Tudja, Petar; Khan, M. Zahirul I.; Mestrovic, Ernest; Horvat, Michaela; Golja, Petra
CORPORATE SOURCE: Department of Pharmaceutical Technology, Research and Development, PLIVA d.d., Zagreb, 10000, Croatia
SOURCE: Chemical & Pharmaceutical Bulletin (2001), 49(10), 1245-1250
CODEN: CPBTAL; ISSN: 0009-2363
PUBLISHER: Pharmaceutical Society of Japan
DOCUMENT TYPE: Journal
LANGUAGE: English
OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS

RECORD (12 CITINGS)
REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 4 ibib abs

L18 ANSWER 4 OF 5 CA COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 143:199868 CA
TITLE: Solid forms of montelukast
INVENTOR(S): Mestrovic, Ernest; Horvat, Michaela ; Devcic, Maja; Avdagic, Amir; Ciccic, Dominik; Marinkovic, Marina
PATENT ASSIGNEE(S): Pliva- Istrazivanje I Razvoj D.O.O., Croatia
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005073194	A2	20050811	WO 2005-HR5	20050119
WO 2005073194	A3	20060504		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1709001	A2	20061011	EP 2005-702162	20050119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
US 20070225325	A1	20070927	US 2007-587537	20070607
PRIORITY APPLN. INFO.:			US 2004-540307P P	20040128
			WO 2005-HR5 W	20050119

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB The present invention relates to a new crystalline form and new amorphous forms of montelukast acid, to a process for their preparation, to pharmaceutical formulations containing them. Montelukast was prepared by the treatment of its sodium salt with a citric acid buffer. A crystalline form the acid was obtained which was characterized by x-ray crystallog.
OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> sel rn
E1 THROUGH E12 ASSIGNED

```
=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         31.71     312.50

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                         -0.80      -4.80

FILE 'REGISTRY' ENTERED AT 10:38:20 ON 19 APR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   18 APR 2010  HIGHEST RN 1219538-51-8
DICTIONARY FILE UPDATES:  18 APR 2010  HIGHEST RN 1219538-51-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s e1-e12
             1 1173658-28-0/BI
               (1173658-28-0/RN)
             1 1173658-29-1/BI
               (1173658-29-1/RN)
             1 120-46-7/BI
               (120-46-7/RN)
             1 151767-02-1/BI
               (151767-02-1/RN)
             1 15307-79-6/BI
               (15307-79-6/RN)
             1 15362-40-0/BI
               (15362-40-0/RN)
             1 158966-92-8/BI
               (158966-92-8/RN)
             1 169590-42-5/BI
               (169590-42-5/RN)
             1 329900-75-6/BI
               (329900-75-6/RN)
             1 6138-23-4/BI
               (6138-23-4/RN)
             1 7440-59-7/BI
```

(7440-59-7/RN)
1 7727-37-9/BI
(7727-37-9/RN)
L19 12 (1173658-28-0/BI OR 1173658-29-1/BI OR 120-46-7/BI OR 151767-02-1/BI OR 15307-79-6/BI OR 15362-40-0/BI OR 158966-92-8/BI OR 1695 90-42-5/BI OR 329900-75-6/BI OR 6138-23-4/BI OR 7440-59-7/BI OR 7727-37-9/BI)

=> file ca
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.49 312.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE 0.00 -4.80

FILE 'CA' ENTERED AT 10:38:43 ON 19 APR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 15 Apr 2010 VOL 152 ISS 17
FILE LAST UPDATED: 15 Apr 2010 (20100415/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2010

CA now includes complete International Patent Classification (IPC) reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l19
L20 505232 L19

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.49 313.48

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL

	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-4.80

FILE 'REGISTRY' ENTERED AT 10:38:52 ON 19 APR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 APR 2010 HIGHEST RN 1219538-51-8
DICTIONARY FILE UPDATES: 18 APR 2010 HIGHEST RN 1219538-51-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d l19

L19 ANSWER 1 OF 12 REGISTRY COPYRIGHT 2010 ACS on STN
RN 1173658-29-1 REGISTRY
ED Entered STN: 09 Aug 2009
CN Cadmium, bis(2,4-pentanedionato-κO2,κO4)bis[1,1'-(sulfinyl-
κO)bis[methane]]-, (OC-6-22)- (CA INDEX NAME)
MF C14 H26 Cd O6 S2
CI CCS
SR CA
LC STN Files: CA, CAPLUS, CASREACT



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d 2 l19

L19 ANSWER 2 OF 12 REGISTRY COPYRIGHT 2010 ACS on STN
RN 1173658-28-0 REGISTRY
ED Entered STN: 09 Aug 2009
CN Cadmium, diaquabis(2,4-pentanedionato-κO2,κO4)- (CA INDEX NAME)
MF C10 H18 Cd O6
CI CCS
SR CA
LC STN Files: CA, CAPLUS, CASREACT



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d 3-12 l19

L19 ANSWER 3 OF 12 REGISTRY COPYRIGHT 2010 ACS on STN
RN 329900-75-6 REGISTRY
ED Entered STN: 04 Apr 2001
CN Synthetase, prostaglandin endoperoxide, 2 (CA INDEX NAME)
OTHER NAMES:
CN Arachidonate cyclooxygenase 2
CN COX 2
CN COX-2
CN COX2
CN Cyclooxygenase 2
CN Cyclooxygenase II
CN Prostaglandin endoperoxidase synthase 2
CN Prostaglandin endoperoxide H synthase-2
CN Prostaglandin endoperoxide synthase-2
CN Prostaglandin endoperoxide synthetase 2
CN Prostaglandin G/H synthase-2
CN Prostaglandin H synthase-2
MF Unspecified
CI MAN
SR CA

LC STN Files: BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, TOXCENTER, USPAT2, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

17870 REFERENCES IN FILE CA (1907 TO DATE)
19 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
18004 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L19 ANSWER 4 OF 12 REGISTRY COPYRIGHT 2010 ACS on STN
RN 169590-42-5 REGISTRY
ED Entered STN: 02 Nov 1995
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)
OTHER NAMES:
CN 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide
CN Celebra
CN Celebrex
CN Celecox
CN Celecoxib
CN Celocoxib
CN Eurocox
CN Medicoxib
CN SC 58635
CN Xilebao
CN YM 177
DR 184007-95-2, 194044-54-7
MF C17 H14 F3 N3 O2 S
CI COM
SR US Adopted Names Council (USAN)
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CABA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, PATDPASPC, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3889 REFERENCES IN FILE CA (1907 TO DATE)
87 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3926 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L19 ANSWER 5 OF 12 REGISTRY COPYRIGHT 2010 ACS on STN
RN 158966-92-8 REGISTRY
ED Entered STN: 15 Nov 1994
CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cyclopropaneacetic acid, 1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, [R-(E)]-
OTHER NAMES:
CN 1-[[[(R)-1-[3-[(E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid
CN 2-[1-[[[(1R)-1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropyl]acetic acid
CN Montelukast
CN [1-[[[(1R)-1-[3-[(E)-2-(7-Chloroquinolin-2-yl)vinyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropyl]acetic acid
FS STEREOSEARCH
MF C35 H36 Cl N O3 S
CI COM
SR World Health Organization (WHO)
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CIN, DDFU, DRUGU, EMBASE, HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

849 REFERENCES IN FILE CA (1907 TO DATE)
21 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
852 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L19 ANSWER 6 OF 12 REGISTRY COPYRIGHT 2010 ACS on STN
RN 151767-02-1 REGISTRY
ED Entered STN: 16 Dec 1993
CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, sodium salt (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, monosodium salt (9CI)
CN Cyclopropaneacetic acid, 1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, monosodium salt, [R-(E)]-
OTHER NAMES:
CN 1-[[[(R)-1-[3-[(E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid sodium salt
CN 2-[1-[[[(1R)-1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropyl]acetic acid sodium salt
CN MK 476
CN Momazol
CN Montair
CN Montelukast monosodium salt
CN Montelukast sodium
CN Shantroz
CN Singulair
CN Sodium 2-[1-[[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)vinyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropyl]acetate
CN Sodium montelukast
FS STEREOSEARCH
MF C35 H36 Cl N O3 S . Na
CI COM
SR US Adopted Names Council (USAN)
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, EMBASE, HSDB*, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PATDPASPC, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
CRN (158966-92-8)

Absolute stereochemistry.
Double bond geometry as shown.



● Na

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

316 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
320 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L19 ANSWER 7 OF 12 REGISTRY COPYRIGHT 2010 ACS on STN
RN 15362-40-0 REGISTRY
ED Entered STN: 16 Nov 1984
CN 2H-Indol-2-one, 1-(2,6-dichlorophenyl)-1,3-dihydro- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Indolinone, 1-(2,6-dichlorophenyl)- (8CI)
OTHER NAMES:
CN 1-(2,6-Dichlorophenyl)-2-indolinone
CN 1-(2,6-Dichlorophenyl)oxindole
CN N-(2,6-Dichlorophenyl)-2-indolinone
CN NSC 621845
MF C14 H9 Cl2 N O
LC STN Files: ANABSTR, BEILSTEIN*, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, IFICDB, IFIPAT, IFIUDB, RTECS*, TOXCENTER, USPATFULL, USPATOLD
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

80 REFERENCES IN FILE CA (1907 TO DATE)
81 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L19 ANSWER 8 OF 12 REGISTRY COPYRIGHT 2010 ACS on STN
RN 15307-79-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, sodium salt (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Acetic acid, [o-(2,6-dichloroanilino)phenyl]-, monosodium salt (8CI)
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, monosodium salt (9CI)
OTHER NAMES:
CN 2-(2,6-Dichloroanilino)phenylacetic acid sodium salt
CN Abitren
CN Allvoran
CN Assaren
CN Benfofen
CN Declophen
CN Dedolor
CN Deflamat
CN Delphimix
CN Diacron
CN Dichronic
CN Diclo-Phlogont
CN Diclo-Puren
CN Diclobene
CN Diclobenin
CN Dicloberl
CN Dicloberl Retard
CN Diclodyn
CN Diclofen SR 100
CN Diclofenac retard
CN Diclofenac sodium
CN Diclofenac sodium salt
CN Diclofenac-Na Emulgel
CN Diclofenacsodium Emulgel
CN Dicloflex
CN Diclokalium
CN Diclon
CN Diclophenac sodium
CN Dicloran CP
CN Dicloran Plus
CN Diclord
CN Diclorep
CN Dicloreum
CN diclotard
CN Diklovit
CN Dolobasan
CN Duravolten
CN Dyclo
CN Dyloject
CN Effekton
CN Evofenac

CN Feloran
CN Fortfen
CN GP 45840
CN Hyanalgese D
CN Inflaban
CN Kriplex
CN Modifenac
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
DR 1147187-62-9
MF C14 H11 Cl2 N O2 . Na
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, PATDPASPC, PIRA, PROMT, PROUSDDR, PS, RTECS*, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, USPATOLD
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (15307-86-5)



● Na

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3251 REFERENCES IN FILE CA (1907 TO DATE)
29 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3262 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L19 ANSWER 9 OF 12 REGISTRY COPYRIGHT 2010 ACS on STN
RN 7727-37-9 REGISTRY
ED Entered STN: 16 Nov 1984
CN Nitrogen (CA INDEX NAME)
OTHER NAMES:
CN Diatomic nitrogen
CN Dinitrogen
CN Molecular nitrogen
CN Nitrogen (N2)
CN Nitrogen gas
CN Nitrogen nutrition (plant)
CN Nitrogen-14
DR 778548-56-4, 882528-56-5, 951778-24-8, 745765-07-5, 794449-54-0, 1119449-41-0, 161728-27-4, 156457-45-3, 93037-13-9, 263005-65-8

MF N2
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CABA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, TULSA, ULIDAT, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

370924 REFERENCES IN FILE CA (1907 TO DATE)
14984 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
372293 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L19 ANSWER 10 OF 12 REGISTRY COPYRIGHT 2010 ACS on STN
RN 7440-59-7 REGISTRY
ED Entered STN: 16 Nov 1984
CN Helium (CA INDEX NAME)
OTHER NAMES:
CN Atomic helium
CN Helium-4
CN o-Helium
CN p-Helium
DR 494798-31-1
MF He
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CABA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, PIRA, PROMT, RTECS*, TOXCENTER, TULSA, USAN, USPAT2, USPATFULL, USPATOLD
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

He

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

127416 REFERENCES IN FILE CA (1907 TO DATE)
4813 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
127878 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L19 ANSWER 11 OF 12 REGISTRY COPYRIGHT 2010 ACS on STN

RN 6138-23-4 REGISTRY
ED Entered STN: 16 Nov 1984
CN α-D-Glucopyranoside, α-D-glucopyranosyl, hydrate (1:2) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN α-D-Glucopyranoside, α-D-glucopyranosyl, dihydrate (9CI)
CN Trehalose, dihydrate (8CI)
OTHER NAMES:
CN α,α-Trehalose dihydrate
CN α-D-Glucopyranosyl α-D-glucopyranoside dihydrate
CN D-(+)-Trehalose dihydrate
FS STEREOSEARCH
DR 219843-81-9
MF C12 H22 O11 . 2 H2 O
CI COM
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, DETHERM*, IPA, MRCK*, RTECS*, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
CRN (99-20-7)

Absolute stereochemistry. Rotation (+).



● 2 H_2O

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

217 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
217 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L19 ANSWER 12 OF 12 REGISTRY COPYRIGHT 2010 ACS on STN
RN 120-46-7 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1,3-Propanedione, 1,3-diphenyl- (CA INDEX NAME)
OTHER NAMES:
CN ω-Benzoylacetophenone
CN 1,3-Diphenyl-1,3-propanedione
CN 2-Benzoylacetophenone
CN AD 158
CN DBM

```
CN   Dibenzoylmethane
CN   Karenz DK 2
CN   NSC 406806
CN   NSC 52984
CN   NSC 6266
CN   Phenyl phenacyl ketone
CN   Rhodiastab 83
DR   61346-73-4
MF   C15 H12 O2
CI   COM
LC   STN Files:   AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS,
       CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DETHERM*,
       EMBASE, GMELIN*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MRCK*, MSDS-OHS, PIRA,
       PROMT, RTECS*, SPECINFO, TOXCENTER, USPAT2, USPATFULL, USPATOLD
         (*File contains numerically searchable property data)
     Other Sources:   DSL**, EINECS**, TSCA**
         (**Enter CHEMLIST File for up-to-date regulatory information)
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
           3973 REFERENCES IN FILE CA (1907 TO DATE)
            712 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
           3987 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> d his

     (FILE 'HOME' ENTERED AT 10:17:37 ON 19 APR 2010)

     FILE 'REGISTRY' ENTERED AT 10:17:46 ON 19 APR 2010
L1             8 S MONTELUKAST
L2             1 S 158966-92-8/RN

     FILE 'CA' ENTERED AT 10:22:29 ON 19 APR 2010
L3           849 S L2
L4             5 S L2 AND CRYSTALLINE
L5             0 S MONTELUKAST ACETIC ACID

     FILE 'REGISTRY' ENTERED AT 10:31:48 ON 19 APR 2010
L6             0 S MONTELUKAST ACETIC ACID
L7             0 S "1-((((1(R)-(3-(2-(7-CHLORO-2-QUINOLINYL)THEYNYL)-PHENYL)-3-(2

     FILE 'CA' ENTERED AT 10:33:42 ON 19 APR 2010
L8             0 S "1-((((1(R)-(3-(2-(7-CHLORO-2-QUINOLINYL)THEYNYL)-PHENYL)-3-(2
L9             0 S HR05/00005
L10            0 S 20070225325

     FILE 'USPATFULL' ENTERED AT 10:34:52 ON 19 APR 2010
```

```
L11           0 S 20070225325
L12           0 S SOLID FORMS OF MONTELUKAST ACKD
L13           1 S SOLID FORMS OF MONTELUKAST ACID

     FILE 'CA' ENTERED AT 10:35:22 ON 19 APR 2010
L14           0 S L13
L15           0 S US 20070225325
L16           0 S MESTROVIC/AU
L17          95 S MESTROVIC?/AU
L18           5 S L17 AND HORVAT?/AU
                SEL RN

     FILE 'REGISTRY' ENTERED AT 10:38:20 ON 19 APR 2010
L19          12 S E1-E12

     FILE 'CA' ENTERED AT 10:38:43 ON 19 APR 2010
L20      505232 S L19

     FILE 'REGISTRY' ENTERED AT 10:38:52 ON 19 APR 2010

=> s l3 and amorphphous
             0 AMORPHPHOUS
L21          0 L3 AND AMORPHPHOUS

=> s amorphous and l3
            21 AMORPHOUS
L22          0 AMORPHOUS AND L3

=> s "form i" and l3
        517843 "FORM"
        652373 "I"
          1304 "FORM I"
                 ("FORM"(W)"I")
L23          0 "FORM I" AND L3

=> file ca
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     50.14     363.62

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                      0.00      -4.80

FILE 'CA' ENTERED AT 10:42:43 ON 19 APR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)
```

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Apr 2010 VOL 152 ISS 17
FILE LAST UPDATED: 15 Apr 2010 (20100415/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2010

CA now includes complete International Patent Classification (IPC) reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s amorphous and l3
299887 AMORPHOUS
L24 13 AMORPHOUS AND L3

=> s crystalline and l3
91832 CRYSTALLINE
L25 5 CRYSTALLINE AND L3

=> s l24 or l25
L26 15 L24 OR L25

=> d ibib abs hitstr 1-15

L26 ANSWER 1 OF 15 CA COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 151:381196 CA
TITLE: Process for preparation of montelukast and removal of impurities
INVENTOR(S): Halama, Ales; Bouskova, Olga; Gibala, Petr; Jirman, Josef
PATENT ASSIGNEE(S): Zentiva, K.S., Czech Rep.
SOURCE: PCT Int. Appl., 44pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009111998	A2	20090917	WO 2009-CZ38	20090311
WO 2009111998	A3	20100325		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,

IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: CZ 2008-167 A 20080314

AB The present invention pertains to a process for the preparation of montelukast and the removal of specific impurities, which are decomposition products of montelukast and byproducts from preparation process. For example, montelukast sodium (preparation given) contaminated by impurities was dissolved in toluene, washed with 0.5 M tartaric acid, water, and the obtained toluene solution was dried over sodium sulfate. The desiccant was filtered off and iso-propylamine in heptane was added to the filtrate. After 1 h of stirring, more heptane was added to the separated suspension, and the stirring was continued for 1 h, then filtration was performed, and the cake was washed with heptane, vacuum dried at room temperature to afford salt of montelukast with iso-propylamine, which can be purified by recrystn. from isopropanol. The crystalline salt of montelukast with iso-propylamine in toluene was treated with sodium tert-butoxide at 30 - 35 °C for 45 min, then filtration was performed and the clear filtrate was added dropwise to intensively stirred heptane. The obtained suspension was stirred for another hour and then subjected to filtration and vacuum drying to give pure montelukast sodium as an amorphous powder.

IT 158966-92-8, Montelukast
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of montelukast and removal of impurities)

RN 158966-92-8 CA

CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L26 ANSWER 2 OF 15 CA COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 150:501196 CA
TITLE: Novel crystalline salts of montelukast
INVENTOR(S): O'Shea, Paul
PATENT ASSIGNEE(S): Merck Frosst Canada Ltd., Can.
SOURCE: PCT Int. Appl., 31pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009052625	A1	20090430	WO 2008-CA1875	20081023

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2007-342P P 20071025

AB The present application relates to crystalline 1,2-ethanedisulfonic acid salt and N,N'-dibenzylethylenediamine salt of montelukast. The salts are useful as therapeutic agents for the treatment of leukotriene mediated diseases and disorders. This application also relates to processes and intermediates for preparing the said salts and pharmaceutical compns. comprising the salts and optionally other therapeutic agents.

IT 158966-92-8, Montelukast
RL: RCT (Reactant); RACT (Reactant or reagent)
(novel crystalline salts of montelukast)

RN 158966-92-8 CA

CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 3 OF 15 CA COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 150:501152 CA
TITLE: Crystalline montelukast cyclopropylamine salt for preparation of pure amorphous sodium salt
INVENTOR(S): Huguet Clotet, Juan; Peirats Masia, Jordi
PATENT ASSIGNEE(S): Inke, S.A., Spain
SOURCE: PCT Int. Appl., 29pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009053424	A1	20090430	WO 2008-EP64345	20081023
WO 2009053424	A9	20090806		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 2053043	A1	20090429	EP 2007-380294	20071026

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS

PRIORITY APPLN. INFO.: EP 2007-380294 A 20071026
OTHER SOURCE(S): CASREACT 150:501152; MARPAT 150:501152
GI



I

AB The present invention refers to the novel cyclopropylamine salt of montelukast (I) in crystalline form and its use in the process for the preparation of highly pure amorphous montelukast sodium. I is prepared from

[1-[1-(R)-(3-bromophenyl)-3-[2-(1-hydroxy-1-methylethyl)phenyl]propylsulfanylmethyl]cyclopropyl]acetic acid and 7-chloro-2-vinylquinoline. I is treated with cyclopropylamine to give a polymorphic form and this is converted to the sodium salt.

IT 158966-92-8P, Montelukast
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(crystalline montelukast cyclopropylamine salt for preparation of pure amorphous sodium salt)

RN 158966-92-8 CA

CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 4 OF 15 CA COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 150:456452 CA
TITLE: Crystalline montelukast cyclopropylamine salt for preparation of pure amorphous sodium salt
INVENTOR(S): Huguet Clotet, Joan; Peirats Masia, Jordi
PATENT ASSIGNEE(S): Inke, S.A., Spain
SOURCE: Eur. Pat. Appl., 17pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 2053043	A1	20090429	EP 2007-380294	20071026
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
US 20090111849	A1	20090430	US 2007-965730	20071227
WO 2009053424	A1	20090430	WO 2008-EP64345	20081023

WO 2009053424 A9 20090806
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRIORITY APPLN. INFO.: EP 2007-380294 A 20071026
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB The present invention refers to the novel cyclopropylamine salt of montelukast (I) in crystalline form and its use in the process for the preparation of highly pure amorphous montelukast sodium. I is prepared from [1-[1-(R)-(3-bromophenyl)-3-[2-(1-hydroxy-1-methylethyl)phenyl]propylsulfanylmethyl]cyclopropyl]acetic acid and 7-chloro-2-vinylquinoline. I is treated with cyclopropylamine to give a polymorphic form and this is converted to the sodium salt.
IT 158966-92-8P, Montelukast
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(crystalline montelukast cyclopropylamine salt for preparation of pure amorphous sodium salt)
RN 158966-92-8 CA
CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 5 OF 15 CA COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 150:129333 CA
TITLE: A method for isolation and purification of montelukast

for treatment of asthma and allergies
INVENTOR(S): Halama, Ales; Jirman, Josef; Petrickova, Hana
PATENT ASSIGNEE(S): Zentiva, A. S., Czech Rep.
SOURCE: PCT Int. Appl., 25pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009006861	A2	20090115	WO 2008-CZ81	20080708
WO 2009006861	A3	20090522		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 2173718	A2	20100414	EP 2008-784159	20080708
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: CZ 2007-455 A 20070709
WO 2008-CZ81 W 20080708
OTHER SOURCE(S): CASREACT 150:129333

AB A method of isolation of montelukast from reaction mixts. is provided, comprising conversion of the crude substance to well-crystallizing salts with primary amines in the environment of at least one organic solvent and acetonitrile, followed by re-crystallization of these salts with simultaneous removal of chemical impurities and use of the CP salts of montelukast with primary amines for direct transformation to the pharmaceutically useful amorphous form of montelukast sodium for the preparation of a composition for treatment of asthma and allergies. Thus, a crude montelukast sodium was prepared from a reaction mixture containing 6.62 g of [1-(mercaptomethyl)cyclopropyl]acetic acid, a base (8.50 g of sodium tert-butoxide), 26 mL of PEG-600 and 26 g of 2-[3-(S)-[3-[2-(7-chloroquinolinyl)ethenyl]phenyl]-3-methanesulfonyloxypropyl]phenyl-2-propanol in toluene at -10° (yield 85.7%). The crude product was treated with isopropylamine using acetonitrile and heptane resulting in montelukast isopropylamine (yield 75%, HPLC purity 93.5%).

IT 158966-92-8P, Montelukast
RL: IMF (Industrial manufacture); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(isolation and purification of montelukast and sodium salt through conversion to and crystallization of salts with primary amines for treatment of asthma and allergies)

RN 158966-92-8 CA
CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 158966-92-8DP, Montelukast, salts with alkali metals or primary amines
RL: IMF (Industrial manufacture); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(isolation and purification of montelukast and sodium salt through conversion to and crystallization of salts with primary amines for treatment of
asthma and allergies)
RN 158966-92-8 CA
CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L26 ANSWER 6 OF 15 CA COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 149:582517 CA
TITLE: Solid dosage forms of pharmaceutical carriers
INVENTOR(S): Cengic, Dzenana; Darmuzey, Olivia; Macleod, Graeme
PATENT ASSIGNEE(S): FMC Corporation, USA
SOURCE: PCT Int. Appl., 43pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008140460	A1	20081120	WO 2007-US11762	20070516

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: WO 2007-US11762 20070516

AB A solid form comprising at least one film enrobing a compacted fill material having at least one active material contained in a matrix and having low friability, a d. of at least 0.5 g/mL based on the total solid volume of the solid form and a tensile strength less than 0.9 MPa and which exhibits a controlled release profile for release of the active material. Zero order release may be achieved.

IT 158966-92-8, Montelukast
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solid dosage forms of pharmaceutical carriers)

RN 158966-92-8 CA

CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 7 OF 15 CA COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 149:556455 CA
TITLE: Process for the preparation of amorphous Montelukast sodium salt wherein crystalline forms of methanesulfonate intermediate and Montelukast are not isolated.
INVENTOR(S): Zyla, Daniel; Rynkiewicz, Robert; Krzyzanowski, Mariusz; Ramza, Jan
PATENT ASSIGNEE(S): Zaklady Farmaceutyczne Polpharma S. A., Pol.
SOURCE: PCT Int. Appl., 22pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008136693	A2	20081113	WO 2008-PL33	20080430
WO 2008136693	A3	20081231		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 2142508	A2	20100113	EP 2008-741772	20080430

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR

US 20100069641	A1	20100318	US 2009-597746		20091026
IN 2009KN04035	A	20100319	IN 2009-KN4035		20091120
CN 101679268	A	20100324	CN 2008-80017789		20091127
PRIORITY APPLN. INFO.:			PL 2007-382346	A	20070502
			WO 2008-PL33	W	20080430

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 149:556455
AB Amorphous Montelukast sodium was prepared by (1) reaction of 2-[2-(3S)-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-(hydroxypropyl)phenyl]-2-propanol with MeSO2Cl in the presence of a tertiary amine, (2) filtration of precipitated tertiary amine salt and reaction of the crude methanesulfonate ester with [1-(mercaptomethyl)cyclopropyl]acetic acid disodium salt, (3) isolation of crystalline 1-[[[(1R)-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid tert-butylamine salt, (4) purification of this salt until the product has high pharmaceutical purity, and (5) conversion of the purified salt to the title compound
IT 158966-92-8P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for the preparation of amorphous Montelukast sodium salt wherein crystalline forms of methanesulfonate intermediate and Montelukast are not isolated)
RN 158966-92-8 CA
CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L26 ANSWER 8 OF 15 CA COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 146:169239 CA
TITLE: Preparation of montelukast
INVENTOR(S): Padi, Pratap Reddy; Bollikonda, Satyanarayana; Srivastava, Alok Kumar; Kasturi, Ravi Kumar; Jinna, Rajender Reddy; Mopidevi, Narsimha Naidu
PATENT ASSIGNEE(S): Dr. Reddy's Laboratories Ltd., India; Dr. Reddy's Laboratories, Inc.
SOURCE: PCT Int. Appl., 29pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007012075	A2	20070125	WO 2006-US28431	20060720
WO 2007012075	A3	20070927		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2006269861	A1	20070125	AU 2006-269861	20060720
CA 2616129	A1	20070125	CA 2006-2616129	20060720
EP 1912499	A2	20080423	EP 2006-788155	20060720
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
US 20080214823	A1	20080904	US 2008-996453	20080122
KR 2008033425	A	20080416	KR 2008-703923	20080219

PRIORITY APPLN. INFO.:
IN 2005-CH966 A 20050720
US 2005-735267P P 20051110
IN 2006-CH455 A 20060314
US 2006-806822P P 20060710
US 2004-566603P P 20040430
US 2004-584675P P 20040702
WO 2006-US28431 W 20060720

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB A process for preparing amorphous montelukast sodium comprises removing solvent from a solution comprising montelukast sodium using agitated thin film drying. Montelukast tertiary butylamine was reacted with sodium hydroxide to obtain montelukast sodium, yield=75.4%.

IT 158966-92-8P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of montelukast)

RN 158966-92-8 CA

CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L26 ANSWER 9 OF 15 CA COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 144:488539 CA
TITLE: Process for the preparation of amorphous montelukast sodium by the neutralization of montelukast free acid with sodium hydroxide followed by vacuum or spray drying
INVENTOR(S): Chava, Satyanaryana; Gorantla, Seeta Ramanjaneyulu; Indukuri, Venkata, Sunil Kumar
PATENT ASSIGNEE(S): Matrix Laboratories Ltd, India
SOURCE: PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006054317	A1	20060526	WO 2005-IN366	20051111
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
IN 2004CH01221	A	20061027	IN 2004-CH1221	20041119
EP 1831171	A1	20070912	EP 2005-823577	20051111
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 20080146809	A1	20080619	US 2007-794277	20070622

PRIORITY APPLN. INFO.:		
IN 2004-CH1221	A	20041119
WO 2005-IN366	W	20051111

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB A process for the preparation of amorphous montelukast sodium is described which comprises dissolving montelukast free acid in an organic solvent, converting it into its sodium salt by neutralization of the free acid with sodium hydroxide, followed by vacuum drying or spray drying the solution Alternatively the amorphous form may be prepared by the dissoln. of montelukast sodium in an organic solvent followed by vacuum drying or spray drying the solution
IT 158966-92-8, Montelukast
RL: RCT (Reactant); RACT (Reactant or reagent)
(process for the preparation of amorphous montelukast sodium by the neutralization of montelukast free acid with sodium hydroxide followed by vacuum or spray drying)
RN 158966-92-8 CA
CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 10 OF 15 CA COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 144:40807 CA
TITLE: Process for preparation of amorphous form of a drug
INVENTOR(S): Szabo, Csaba; Szoke, Szabolcs; Gyuricza, Lorant; Singer, Claude
PATENT ASSIGNEE(S): Teva Gyogyszergyar Reszvenytarsasag, Hung.
SOURCE: U.S. Pat. Appl. Publ., 13 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 20050272768	A1	20051208	US 2005-143312		20050601
US 7589128	B2	20090915			
CA 2560984	A1	20051215	CA 2005-2560984		20050601
WO 2005117837	A1	20051215	WO 2005-US19485		20050601
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1641438	A1	20060405	EP 2005-758626		20050601
EP 1641438	B1	20100224			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU					
CN 1938005	A	20070328	CN 2005-80009910		20050601
JP 2008500405	T	20080110	JP 2007-527596		20050601
AT 458476	T	20100315	AT 2005-758626		20050601
IN 2006DN04990	A	20070713	IN 2006-DN4990		20060830
MX 2006010084	A	20070301	MX 2006-10084		20060904
KR 2006123772	A	20061204	KR 2006-718664		20060912
PRIORITY APPLN. INFO.:			US 2004-576216P	P	20040601
			US 2004-583778P	P	20040628
			US 2004-599700P	P	20040805
			WO 2005-US19485	W	20050601

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Provided is a process for preparation of amorphous form of an active pharmaceutical ingredient. Montelukast was treated with NaOH powder and acetone, and the product, the sodium salt, obtained was dissolved in acetone, and the product was characterized.

IT 158966-92-8, Montelukast
RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(process for preparation of amorphous form of drugs)

RN 158966-92-8 CA

CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 67 THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 11 OF 15 CA COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 143:235400 CA
TITLE: Montelukast free acid polymorphs
INVENTOR(S): Niddam-Hildesheim, Valerie; Aronhime, Judith; Chen, Kobi
PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005074935	A1	20050818	WO 2005-US2898	20050131
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2554572	A1	20050818	CA 2005-2554572	20050131
US 20050187243	A1	20050825	US 2005-48276	20050131
EP 1708708	A1	20061011	EP 2005-712362	20050131
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
EP 1760077	A1	20070307	EP 2005-112284	20050131
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,				

HR, LV, MK, YU

JP 2007518826	T	20070712	JP 2006-551524		20050131
CN 101005839	A	20070725	CN 2005-80001827		20050131
MX 2006008584	A	20070416	MX 2006-8584		20060728
IN 2006DN04489	A	20070824	IN 2006-DN4489		20060803
KR 2006117356	A	20061116	KR 2006-716358		20060814
PRIORITY APPLN. INFO.:			US 2004-540840P	P	20040130
			US 2004-582237P	P	20040622
			EP 2005-712362	A3	20050131
			WO 2005-US2898	W	20050131

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention relates to amorphous and polymorphic forms of montelukast free acid. Amorphous montelukast was prepared from its Na salt dissolved in water and treatment with HCl.

IT 158966-92-8, Montelukast
RL: FMU (Formation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
(montelukast free acid polymorphs)

RN 158966-92-8 CA

CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 12 OF 15 CA COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER:	143:199868 CA
TITLE:	Solid forms of montelukast
INVENTOR(S):	Mestrovic, Ernest; Horvat, Michaela; Devcic, Maja; Avdagic, Amir; Ciccic, Dominik; Marinkovic, Marinka
PATENT ASSIGNEE(S):	Pliva- Istrazivanje I Razvoj D.O.O., Croatia
SOURCE:	PCT Int. Appl., 30 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005073194	A2	20050811	WO 2005-HR5	20050119
WO 2005073194	A3	20060504		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1709001	A2	20061011	EP 2005-702162	20050119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
US 20070225325	A1	20070927	US 2007-587537	20070607
PRIORITY APPLN. INFO.:			US 2004-540307P P	20040128
			WO 2005-HR5 W	20050119

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention relates to a new crystalline form and new amorphous forms of montelukast acid, to a process for their preparation, to pharmaceutical formulations containing them. Montelukast was prepared by the treatment of its sodium salt with a citric acid buffer. A crystalline form the acid was obtained which was characterized by x-ray crystallog.

IT 158966-92-8P, Montelukast
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(solid forms of montelukast)

RN 158966-92-8 CA

CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 13 OF 15 CA COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 142:38157 CA
TITLE: An improved method for preparation of montelukast acid and sodium salt
INVENTOR(S): Suri, Sanjay; Singh, Jujhhar; Sarin, Gurdeep Singh; Tanwar, Madan Pal; Mahendru, Manu
PATENT ASSIGNEE(S): Morepen Laboratories Limited, India
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004108679	A1	20041216	WO 2003-IN214	20030606
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2528228	A1	20041216	CA 2003-2528228	20030606
AU 2003253247	A1	20050104	AU 2003-253247	20030606
EP 1631550	A1	20060308	EP 2003-817134	20030606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
IN 2005DN05558	A	20091002	IN 2005-DN5558	20051130
US 20070082925	A1	20070412	US 2006-576971	20060425
PRIORITY APPLN. INFO.:			WO 2003-IN214 W	20030606

OTHER SOURCE(S): CASREACT 142:38157

GI



AB The invention relates to a preparation of montelukast acid sodium salt of formula I•Na in amorphous form, useful as leukotriene antagonist (no biol. data). The method comprises of following steps: (a) generating the dilithium dianion of 1-(mercaptomethyl)cyclopropane acetic acid by reacting with alkyl lithium, (b) coupling the said dianion with wet mesylate to get montelukast acid in crude form, (c) obtaining DCHA salt in crude form by adding dicyclohexylamine (DCHA) to crude acid obtained in the above step (b), (d) purifying and converting the said DCHA salt in crude form to montelukast acid in pure form, and (e) reacting the pure montelukast acid in a polar protic solvent with a source of sodium ion followed by evaporating the solvent and triturating of the residue with non-polar water immiscible solvent. For instance, I•Na was obtained from the prepared and purified I and sodium hydroxide with a yield of 98.7% (HPLC purity was 99.42%). The invention proposes industrially feasible and cost-effective process for high-yield and high-purity preparation of I•Na.

IT 158966-92-8P
RL: IMF (Industrial manufacture); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(improved method for preparation of amorphous montelukast acid and sodium salt useful as leukotriene antagonists)

RN 158966-92-8 CA

CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 14 OF 15 CA COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 139:185671 CA
TITLE: Novel anhydrous amorphous forms of montelukast sodium salt
INVENTOR(S): Reguri, Buchi Reddy; Bollikonda, Satyanarayana; Bulusu, Veera Venkata Naga Chandra Sekhar
PATENT ASSIGNEE(S): Reddy's Laboratories Ltd., India; Cord, Janet I.
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003066598	A1	20030814	WO 2003-US3700	20030207
WO 2003066598	A9	20031204		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 2002MA00094	A	20050304	IN 2002-MA94	20020207
AU 2003209043	A1	20030902	AU 2003-209043	20030207
PRIORITY APPLN. INFO.:			IN 2002-MA94 A	20020207
			WO 2003-US3700 W	20030207

AB The present invention relates to novel anhydrous amorphous forms of alkali salts of montelukast, to processes for their preparation, to compns. containing them and to methods of treatment using the same. Montelukast is a leukotriene antagonist, useful as antiasthmatic, antiallergic,

anti-inflammatory and cytoprotective agent.
IT 158966-92-8DP, Montelukast, alkali metal salts
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation, compns., and therapeutic uses of anhydrous amorphous forms of montelukast alkali metal salts)
RN 158966-92-8 CA
CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 158966-92-8P, Montelukast
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, compns., and therapeutic uses of anhydrous amorphous forms of montelukast alkali metal salts)
RN 158966-92-8 CA
CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 15 OF 15 CA COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 137:268473 CA
TITLE: Porous drug matrices and methods of manufacture thereof
INVENTOR(S): Straub, Julie; Altreuter, David; Bernstein, Howard; Chickering, Donald E.; Khattak, Sarwat; Randall, Greg
PATENT ASSIGNEE(S): Acusphere Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U. S. 6,395,300.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20020142050	A1	20021003	US 2002-53929		20020122
US 6395300	B1	20020528	US 1999-433486		19991104
EP 1642572	A1	20060405	EP 2005-27194		20000525
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY					
CN 1823737	A	20060830	CN 2005-10136940		20000525
CN 100376291	C	20080326			
US 6645528	B1	20031111	US 2000-694407		20001023
US 6932983	B1	20050823	US 2000-706045		20001103
ZA 2001010347	A	20030730	ZA 2001-10347		20011218
US 20050048116	A1	20050303	US 2004-924642		20040824
US 20050058710	A1	20050317	US 2004-928886		20040827
PH 1200600163	A	20090824	PH 2006-1200600163		20060322
PRIORITY APPLN. INFO.:			US 1999-136323P	P	19990527
			US 1999-158659P	P	19991008
			US 1999-433486	A2	19991104
			US 2000-186310P	P	20000302
			CN 2000-808161	A3	20000525
			EP 2000-939365	A3	20000525
			PH 2000-1200001402	A3	20000529
			US 2002-53929	A3	20020122

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB Drugs, especially low aqueous solubility drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissoln. of the drug in aqueous media. The drug matrixes preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aqueous solubility, in a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solution and hydrophilic or hydrophobic excipients that stabilize the drug and inhibit crystallization, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of drug. Hydrophobic or hydrophilic excipients may be

selected to stabilize the drug in crystalline form by inhibiting crystal growth or to stabilize the drug in amorphous form by preventing crystallization The pore forming agent can be either a volatile liquid that is immiscible with the drug solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. The resulting porous matrix has a faster rate of dissoln. following administration to a patient, as compared to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration. Thus, 5.46 g of PEG 8000, 0.545 g of prednisone, and 0.055 g of Span 40 were dissolved in 182 mL of methylene chloride. A solution of 3.27 g of ammonium bicarbonate in 18.2 mL of water was added to the organic solution (phase ratio 1:10) and homogenized for 5 min at 16,000 RPM. The resulting emulsion was spray dried on a benchtop spray dryer using an air-atomizing nozzle and nitrogen as the drying gas.

IT 158966-92-8, Montelukast
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(porous drug matrixes and methods of manufacture thereof)

RN 158966-92-8 CA

CN Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)

=> d his

(FILE 'HOME' ENTERED AT 10:17:37 ON 19 APR 2010)

FILE 'REGISTRY' ENTERED AT 10:17:46 ON 19 APR 2010
L1 8 S MONTELUKAST
L2 1 S 158966-92-8/RN

FILE 'CA' ENTERED AT 10:22:29 ON 19 APR 2010
L3 849 S L2

```
L4             5 S L2 AND CRYSTALLINE
L5             0 S MONTELUKAST ACETIC ACID

     FILE 'REGISTRY' ENTERED AT 10:31:48 ON 19 APR 2010
L6             0 S MONTELUKAST ACETIC ACID
L7             0 S "1-((((1(R)-(3-(2-(7-CHLORO-2-QUINOLINYL)THEYNYL)-PHENYL)-3-(2

     FILE 'CA' ENTERED AT 10:33:42 ON 19 APR 2010
L8             0 S "1-((((1(R)-(3-(2-(7-CHLORO-2-QUINOLINYL)THEYNYL)-PHENYL)-3-(2
L9             0 S HR05/00005
L10            0 S 20070225325

     FILE 'USPATFULL' ENTERED AT 10:34:52 ON 19 APR 2010
L11            0 S 20070225325
L12            0 S SOLID FORMS OF MONTELUKAST ACKD
L13            1 S SOLID FORMS OF MONTELUKAST ACID

     FILE 'CA' ENTERED AT 10:35:22 ON 19 APR 2010
L14            0 S L13
L15            0 S US 20070225325
L16            0 S MESTROVIC/AU
L17           95 S MESTROVIC?/AU
L18            5 S L17 AND HORVAT?/AU
                 SEL RN

     FILE 'REGISTRY' ENTERED AT 10:38:20 ON 19 APR 2010
L19           12 S E1-E12

     FILE 'CA' ENTERED AT 10:38:43 ON 19 APR 2010
L20       505232 S L19

     FILE 'REGISTRY' ENTERED AT 10:38:52 ON 19 APR 2010
L21            0 S L3 AND AMORPHPHOUS
L22            0 S AMORPHOUS AND L3
L23            0 S "FORM I" AND L3

     FILE 'CA' ENTERED AT 10:42:43 ON 19 APR 2010
L24           13 S AMORPHOUS AND L3
L25            5 S CRYSTALLINE AND L3
L26           15 S L24 OR L25

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

STN INTERNATIONAL LOGOFF AT 10:47:17 ON 19 APR 2010
```